Followers | 25 |
Posts | 1513 |
Boards Moderated | 0 |
Alias Born | 12/14/2006 |
Tuesday, November 16, 2010 3:53:39 PM
On the basis of these results, the company will proceed with multi-center Phase 2 clinical trials of its product Revascor (TM) delivered by a simple intracoronary infusion in heart attack patients immediately after they undergo a standard angioplasty and stent procedure to open a blocked coronary artery.
The study was performed in the Department of Interventional Cardiology at the Thoraxcenter of the Erasmus University Medical Center in Rotterdam, The Netherlands, one of the world's foremost interventional cardiology centers.
The results showed that a simple intracoronary infusion of the patented Mesenchymal Precursor Cells (MPCs) increased blood vessel numbers, prevented scar formation, and significantly improved heart muscle function after a heart attack preventing heart failure.
"These are the most compelling data that I have ever seen regarding a cell therapy approach in cardiovascular disease in the public domain or in non-disclosed data reports," said the study's Principal Investigator Associate Professor Eric Duckers, Head of Molecular Cardiology at the Thoraxcenter.
In the study, 30 sheep who underwent a large anterior myocardial infarct received an infusion into the coronary arteries of either saline (10 subjects) or allogeneic MPCs, at dosages of 12.5, 25, or 37.5 million cells (7, 7, 6 subjects/group). After two months, myocardial function, as measured by ejection fraction (EF), was significantly higher in every MPC dose group than in controls, with no significant differences noted between any of the dosages. Overall, EF in MPC-treated subjects was a mean of 12 points higher than in saline-treated controls (54.4+/-1.1% vs 42.5+/-3.6%, p<0.001). Similarly, every tested dose significantly reduced left ventricular dilation, with mean end systolic volumes in MPC-treated subjects 66+/-1.0 mL compared with 98.6+/-5.1 mL in saline-treated controls (P<0.001). Moreover, in comparison to controls, every MPC dose significantly reduced scar formation and fibrosis in heart muscle (50% mean reduction, P<0.005), and significantly increased blood vessel formation (69% mean increase in capillary density and 122% mean increase in arterioles, both P<0.001).
Heart attack is the single biggest killer of Americans with approximately 7.3 million American adults having had at least one heart attack and over 1.1 million patients having a first heart attack each year. About 80% now survive the initial heart attack. Most of these patients undergo an early angioplasty of the blocked artery accompanied by implantation of a metal stent to keep the artery open long-term. However, despite this success with early survival, a significant number of the surviving patients subsequently become disabled with heart failure.
Mesoblast's product will be developed as a simple off-the-shelf therapy for use in conjunction with angioplasty and stent procedures to prevent the complication of heart failure in those surviving a major heart attack.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
http://www.mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/64187-ASX-MSB-345623.pdf
http://www.abnnewswire.net/press/en/64187/
Everything I state is just my own opinion so do your own DD.
Buying great stocks is important but buying great stocks at a great price is even more important.
Recent MESO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:14:45 AM
- Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 • GlobeNewswire Inc. • 08/28/2024 11:27:43 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 08/27/2024 11:25:57 PM
- Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 07/31/2024 01:13:29 AM
- FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/23/2024 11:53:49 AM
- Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain • GlobeNewswire Inc. • 07/22/2024 12:45:12 AM
- Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/09/2024 12:37:09 AM
- Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week • GlobeNewswire Inc. • 07/01/2024 05:55:36 AM
- Mesoblast Corporate Presentation at Investor Conference • GlobeNewswire Inc. • 06/03/2024 12:23:37 AM
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 • GlobeNewswire Inc. • 04/30/2024 01:05:17 AM
- FDA Commentary Sends Biotech Soaring During Premarket Hours • AllPennyStocks.com • 03/26/2024 01:25:00 PM
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 03/26/2024 02:34:20 AM
- Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer • GlobeNewswire Inc. • 03/13/2024 11:30:47 PM
- United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) • GlobeNewswire Inc. • 03/10/2024 11:54:12 PM
- Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/28/2024 10:57:09 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 02/15/2024 12:46:40 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 • GlobeNewswire Inc. • 01/31/2024 02:13:34 AM
- Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment • Dow Jones News • 01/19/2024 12:28:00 AM
- United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 01/18/2024 11:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:33:54 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/05/2024 02:57:09 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 12/22/2023 10:13:02 PM
- Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease • GlobeNewswire Inc. • 11/26/2023 11:56:21 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM